Condition

Executive Dysfunction

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials12

Recruiting1

Common interventions20

Lead sponsors shown11

Clinical trials

12 shown

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in DementiaNCT05661084 · 2023-01-24

RECRUITING

Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT).NCT06073717 · 2024-10-01

ACTIVE_NOT_RECRUITING

The Antidepressant Effect of Intermittent Theta Burst Stimulation (iTBS)NCT05516095 · 2022-06-04

COMPLETED

Examining Strategy Monitoring and Remediation TrainingNCT04756388 · 2021-02-01

COMPLETED

COMPuter-assisted Self-training to Improve EXecutive FunctionNCT04229056 · 2020-06-01

ACTIVE_NOT_RECRUITING

High-Speed Yoga and Executive FunctionNCT04215900 · 2020-01-15

COMPLETED

Neuropsychological Development and Executive Functioning of Children Born to HIV- Infected Mothers ( NEUROPSY-HEU )NCT04108728 · 2019-11-19

COMPLETED

Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's DiseaseNCT03285347 · 2017-10-01

COMPLETED

Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)NCT03269110 · 2017-07-01

COMPLETED

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural NetworksNCT03153371 · 2016-04-04

COMPLETED

Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)NCT02416193 · 2015-09-23

TERMINATED

n-3 PUFA for Vascular Cognitive AgingNCT01953705 · 2014-05-01

UNKNOWN

Common interventions

BRIEF SCORE AT INCLUSIONDIAGNOSTIC_TEST1 CholecalciferolDRUG1 Computer-based cognitive rehabilitation (CBCR)BEHAVIORAL1 Computer-based cognitive trainingDEVICE1 Computerized Cognitive TrainingOTHER1 ExerciseBEHAVIORAL1 General computer-based cognitive stimulationBEHAVIORAL1 Health and WellnessBEHAVIORAL1 High-speed yoga multi-directional yogaBEHAVIORAL1 Motor-cognitive TrainingBEHAVIORAL1 Omega 3 PUFADRUG1 PlaceboDRUG1 Sham Transcranial magnet stimulationDEVICE1 SRS 2, CBCL, BRIEF-PDIAGNOSTIC_TEST1 Strategy DevelopmentOTHER1 Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)DEVICE1 Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)DEVICE1 Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)DEVICE1 Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)DEVICE1 Transcranial magnet stimulationDEVICE1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

cholecalciferol1 placebo1

Leading sponsors

Bispebjerg Hospital 2 Hebrew SeniorLife 1 Loyola University 1 Nantes University Hospital 1 Oregon Health and Science University 1 Ottawa Hospital Research Institute 1 University Hospital of North Norway 1 University of California, Los Angeles 1 University of Miami 1 University of Seville 1 University of Toronto 1

Trial status mix

COMPLETED7

ACTIVE_NOT_RECRUITING2

RECRUITING1

TERMINATED1

UNKNOWN1

Phase mix

NA8

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.